Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,204 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,004 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06080854 | AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 108 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 |
| clinicaltrials |
| NCT04033107 | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors | unknown | Phase 2 | 30 | Zhongnan HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06013943 | Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC | unknown | Phase 2 | 30 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03777462 | Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1(BRPCNCC-1) | unknown | Phase 2 | 150 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT04324307 | Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 60 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT04902261 | Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer | unknown | Phase 2 | 140 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05783076 | SBRT Plus vNKT for Pancreatic Cancer | unknown | Phase 2 | 29 | Changhai HospitalOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05023109 | GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC | unknown | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05919095 | A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer | unknown | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04803851 | Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 29 | Peking Union Medical College HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05911425 | Combined Treatment of Treated Bile Duct Cancer(CHOL) | unknown | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05681390 | Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03820310 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | unknown | Phase 2 | 20 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT03553004 | Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial(NIRA-PANC) | unknown | Phase 2 | 18 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05822453 | Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05795920 | Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer | unknown | Phase 2 | 92 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05616494 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer | unknown | Phase 2 | 53 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 22, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT04289792 | Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 27 | Fujian Medical University Union HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04984980 | Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer | unknown | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05679050 | Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05634564 | Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 62 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05620498 | Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05350943 | HAIC Combined With Toripalimab and Donafenib for Advanced BTC | unknown | Phase 2 | 70 | Lu Wang, MD, PhDOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05566743 | A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas | unknown | Phase 2 | 40 | Menoufia UniversityOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05535647 | Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03487016 | First-line Therapy in Metastatic PDAC(FOOTPATH) | unknown | Phase 2 | 270 | Ludwig-Maximilians - University of MunichOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04362449 | Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration | unknown | Phase 2 | 30 | Imperial College Healthcare NHS TrustOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04418739 | Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes | unknown | Phase 2 | 122 | Universiti Kebangsaan Malaysia Medical CentreOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05399394 | Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer(FOLRT) | unknown | Phase 2 | 50 | Campus Bio-Medico UniversityOTHER | 0 | Jun 1, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05298020 | Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Oct 12, 2023source: clinicaltrials